Full history for every metric is available with a Kvantra account

Stock profile

PPD, Inc. (PPD)

Country: United States of AmericaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NASDAQ

Delisted · last close 7 Dec 2021

Current price
47.28 USD-0.06%
Last close 7 Dec 2021
Benchmarks

Key financial summary

Financials in USD
201520162017201820192020TTM
Total revenue$m-2,6803,0013,7494,0314,6815,879
Operating profit$m509654
Net profit$m-18329610448154364
EPS reported$0.441.01
Operating cashflow per share$0.720.72
Capex per share$0.470.47
FCF per share$0.250.25
Free cash flow$m88434
Net debt$m3,6843,070
Book value equity$m-747-424
Book value per share$-2.15-1.18
Number of sharesm346.68359.54
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
201520162017201820192020TTM
Value
P/E TTMx77.77-
P/B LTMx-15.89-40.05
P/S LTMx2.532.89
P/FCF LTMx134.8139.16
EV/EBITDA LTMx22.7421.83
EV/Sales LTMx3.323.41
Earnings Yield LTM%1.29%0.94%
FCF Yield%0.74%2.55%
Quality
ROE%-20.59%-8.92%
ROIC%11.06%11.06%
Operating margin%10.88%10.88%
Gross margin%38.42%38.42%
FCF/Sales%1.88%1.88%
Growth and momentum
EPS Growth YoY%+214.29%+400.50%
Sales Growth YoY%+16.14%+34.71%
Net Income Growth YoY%+221.39%+417.54%
FCF Growth%-71.34%+84.94%
Operating Profit Growth%+21.73%+43.07%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.020.10
Net Debt/EBITDAx5.395.39
EBIT/Net interestx2.352.35
Net debt/market cap%31.05%18.06%
Net debt/Equityx-4.93-7.23
Gross debt/equityx-5.96-10.40

Company overview

PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.

WebsiteN/A
IndustryDrug Manufacturers - Specialty & Generic
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 7 Dec 2021

PPD, Inc. (PPD)

PPD · NASDAQ · Healthcare
47.28 USD-0.06%
Benchmarks
Financialsin USD
20192020TTM
About

PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.

IndustryDrug Manufacturers - Specialty & Generic
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free